Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Data Brief ; 42: 108255, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35669005

ABSTRACT

The accuracy of screening tests for detecting cystic echinococcosis (CE) in livestock depends on characteristics of the host-parasite interaction and the extent of serological cross-reactivity with other taeniid species. The AgB8 kDa protein is considered to be the most specific native or recombinant antigen for immunodiagnosis of ovine CE. A particular DNA fragment coding for rAgB8/2 was identified, that provides evidence of specific reaction in the serodiagnosis of metacestode infection. We developed and validated an IgG Enzyme Linked Immunosorbent Assay (ELISA) test using a recombinant antigen B sub-unit EgAgB8/2 (rAgB8/2) of Echinoccocus granulosus sensu lato (s.l.) to estimate CE prevalence in sheep. A 273 bp DNA fragment coding for rAgB8/2 was expressed as a fusion protein (∼30 kDa) and purified by affinity chromatography. Evaluation of the analytical and diagnostic performance of the ELISA followed the World Organisation for Animal Health (OIE) manual, including implementation of serum panels from: uninfected lambs (n = 79); experimentally infected (with 2,000 E. granulosus s.l. eggs each) sheep with subsequent evidence of E. granulosus cysts by necropsy (n = 36), and animals carrying other metacestode/trematode infections (n = 20). The latter were used to assess the cross-reactivity of rAgB8/2, with these animals being naturally infected with Taenia hydatigena, Thysanosoma actinioides and/or Fasciola hepatica. EgAgB8/2 showed cross-reaction with only one serum sample from a sheep infected with Ta. hydatigena out of the 20 animals tested. Furthermore, the kinetics of the humoral response over time in five 6-month old sheep, each experimentally infected with 2,000 E. granulosus s.l. eggs, was evaluated up to 49 weeks (approximately one year) post infection (n = 5). The earliest detectable IgG response against rAgB8/2 was observed in sera from two and four sheep, 7 and 14 days after experimental infection, respectively. The highest immune response across all five animals was found 16 to 24 weeks post infection.

2.
New Microbiol ; 36(2): 145-51, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23686120

ABSTRACT

A broad coverage influenza vaccine against multiple viral strains based on the viral nucleoprotein (NP) is a goal pursued by many laboratories. If the goal is to formulate the vaccine with recombinant NP it is essential to count on adjuvants capable of inducing cellular immunity. This work have studied the effect of the monophosphoryl lipid A and trehalose dimycolate, known as the Ribi Adjuvant System (RAS), in the immune response induced in mice immunized with recombinant NP. The NP was formulated with RAS and used to immunize BALB/c mice. Immunizations with NP-RAS increased the humoral and cellular immune responses compared to unadjuvanted NP. The predominant antibody isotype was IgG2a, suggesting the development of a Th1 response. Analysis of the cytokines from mice immunized with NP-RAS showed a significant increase in the production of IFN-g and a decreased production of IL-10 and IL-4 compared to controls without RAS. These results are similar to those usually obtained using Freund's adjuvant, known to induce Th1 and CTL responses when co-administered with purified proteins, and suggest that a similar approach may be possible to enhance the performance of a T-cell vaccine containing NP.


Subject(s)
Cell Wall Skeleton/administration & dosage , Cord Factors/administration & dosage , Influenza, Human/immunology , Lipid A/analogs & derivatives , RNA-Binding Proteins/immunology , Th1 Cells/immunology , Viral Core Proteins/immunology , Animals , Antibodies, Viral/immunology , Cell Wall Skeleton/immunology , Cord Factors/immunology , Female , Humans , Immunity, Cellular , Immunization , Influenza Vaccines/administration & dosage , Influenza Vaccines/genetics , Influenza Vaccines/immunology , Influenza, Human/prevention & control , Influenza, Human/virology , Interferon-gamma/immunology , Interleukin-10/immunology , Interleukin-4/immunology , Lipid A/administration & dosage , Lipid A/immunology , Mice , Mice, Inbred BALB C , Nucleocapsid Proteins , RNA-Binding Proteins/administration & dosage , RNA-Binding Proteins/genetics , T-Lymphocytes, Cytotoxic/immunology , Viral Core Proteins/administration & dosage , Viral Core Proteins/genetics
3.
Vaccine ; 31(5): 806-12, 2013 Jan 21.
Article in English | MEDLINE | ID: mdl-23246552

ABSTRACT

The antigenic variation of influenza virus represents a major prevention problem. However, the ectodomain of the protein Matrix 2 (M2e) is nearly invariant in all human influenza A strains and has been considered as a promising candidate for a broadly protective vaccine because antibodies to M2e are protective in animal models. In this work we evaluated the possible use of Brucella abortus lumazine synthase protein (BLS), a highly immunogenic decameric protein, as a carrier of the M2e peptide. Chimeric proteins generated by the fusion of one or four in tandem copies of M2e to BLS were efficiently expressed in Escherichia coli and assembled in decameric subunits similarly to the wild type BLS enzyme, as demonstrated by the comparative circular dichroism spectra and size exclusion chromatography and static light scattering analysis. The M2e peptides were stably exposed at the ten N-terminal ends of each BLS molecule. Immunization of mice with purified chimeras carrying only one M2e (BLS-M2e) copy elicited a significant humoral immune response with the addition of different adjuvants. The fusion of four in tandem copies of the M2e peptide (BLS-4M2e) resulted in similar levels of humoral immune response but in the absence of adjuvant. Survival of mice challenged with live influenza virus was 100% after vaccination with BLS-4M2e adjuvanted with Iscomatrix(®) (P<0.001) and 80% when adjuvanted with alum (P<0.01), while the chimera alone protected 60% of the animals (P<0.05). The approach described in this study is intended as a contribution to the generation of universal influenza immunogens, through a simple production and purification process and using safe carriers that might eventually avoid the use of strong adjuvants.


Subject(s)
Brucella/genetics , Drug Carriers/administration & dosage , Influenza Vaccines/immunology , Multienzyme Complexes/genetics , Repetitive Sequences, Amino Acid/immunology , Viral Matrix Proteins/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Viral/blood , Female , Influenza Vaccines/administration & dosage , Influenza Vaccines/genetics , Mice , Mice, Inbred BALB C , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/prevention & control , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Repetitive Sequences, Amino Acid/genetics , Survival Analysis , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Viral Matrix Proteins/genetics
4.
J Microbiol Biotechnol ; 22(3): 416-21, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22450799

ABSTRACT

Current influenza vaccines elicit antibodies effective against homologous strains, but new strategies are urgently needed for protection against emerging epidemic or pandemic strains. Although influenza vaccine candidates based on the viral nucleoprotein (NP) or matrix protein do not elicit sterilizing immunity, they have the advantage of inducing immunity that may cover a larger number of viral strains. In this study, recombinant NP produced in Escherichia coli was purified and formulated in combination with the adjuvant ISCOMATRIX. This formulation increased a NP-specific immunity in mice, with a Th1 profile, and may constitute a promising low-cost influenza vaccine candidate, with ability to stimulate humoral and cellular immune responses..


Subject(s)
Cholesterol/immunology , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/immunology , Influenza, Human/prevention & control , Nucleoproteins/immunology , Phospholipids/immunology , Saponins/immunology , Viral Proteins/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Viral , Cholesterol/administration & dosage , Drug Combinations , Female , Humans , Immunization , Influenza A Virus, H1N1 Subtype/genetics , Influenza Vaccines/administration & dosage , Influenza Vaccines/genetics , Influenza, Human/immunology , Influenza, Human/virology , Mice , Mice, Inbred BALB C , Nucleoproteins/administration & dosage , Nucleoproteins/genetics , Phospholipids/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Saponins/administration & dosage , Viral Proteins/administration & dosage , Viral Proteins/genetics
5.
Virus Genes ; 44(1): 32-9, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21858463

ABSTRACT

The continuous emergence of new strains of canine parvovirus (CPV), poorly protected by current vaccination, is a concern among breeders, veterinarians, and dog owners around the world. Therefore, the understanding of the genetic variation in emerging CPV strains is crucial for the design of disease control strategies, including vaccines. In this paper, we obtained the sequences of the full-length gene encoding for the main capsid protein (VP2) of 11 canine parvovirus type 2 (CPV-2) Argentine representative field strains, selected from a total of 75 positive samples studied in our laboratory in the last 9 years. A comparative sequence analysis was performed on 9 CPV-2c, one CPV-2a, and one CPV-2b Argentine strains with respect to international strains reported in the GenBank database. In agreement with previous reports, a high degree of identity was found among CPV-2c Argentine strains (99.6-100% and 99.7-100% at nucleotide and amino acid levels, respectively). However, the appearance of a new substitution in the 440 position (T440A) in four CPV-2c Argentine strains obtained after the year 2009 gives support to the variability observed for this position located within the VP2, three-fold spike. This is the first report on the genetic characterization of the full-length VP2 gene of emerging CPV strains in South America and shows that all the Argentine CPV-2c isolates cluster together with European and North American CPV-2c strains.


Subject(s)
Capsid Proteins/genetics , Dog Diseases/virology , Evolution, Molecular , Parvoviridae Infections/veterinary , Parvovirus, Canine/genetics , Amino Acid Sequence , Animals , Argentina , Asia , Capsid Proteins/chemistry , Dogs , Europe , Female , Genetic Variation , Male , Molecular Sequence Data , Parvoviridae Infections/virology , Parvovirus, Canine/chemistry , Parvovirus, Canine/classification , Parvovirus, Canine/isolation & purification , Phylogeny , Sequence Alignment , South America
6.
Virology ; 396(1): 76-84, 2010 Jan 05.
Article in English | MEDLINE | ID: mdl-19896684

ABSTRACT

A type A avian influenza (AI) virus was isolated from dead or severely ill red-winged tinamous (Rhynchotus rufescens) found in a hunting ground in April 2008 in Argentina. The subtype of A/red-winged tinamou/Argentina/MP1/2008 was determined as H1N1 by sequence analysis. The cleavage site of the viral hemagglutinin corresponded to a low pathogenic influenza virus, although the clinical presentation and pathological studies suggest that the virus was pathogenic for red-winged tinamous. Phylogenetic analysis of the viral genome suggested that while the hemagglutinin and neuraminidase genes were related to AIV from North America, the internal genes were most closely related to other South American isolates. These findings support the postulated South American phylogenetic lineage for AIV PB2, PB1, PA, M and NS genes, and suggest that the evolutionary pathways of HA and NA genes involve exchanges between the Northern and Southern hemispheres.


Subject(s)
Birds/virology , Influenza A Virus, H1N1 Subtype/isolation & purification , Animals , Argentina , Base Sequence , Hemagglutination Inhibition Tests , Hemagglutinin Glycoproteins, Influenza Virus/genetics , Influenza A Virus, H1N1 Subtype/classification , Influenza in Birds/diagnosis , Influenza in Birds/pathology , Molecular Sequence Data , Neuraminidase/genetics , Phylogeny , Reverse Transcriptase Polymerase Chain Reaction
7.
Neurotox Res ; 5(5): 369-73, 2003.
Article in English | MEDLINE | ID: mdl-14715455

ABSTRACT

We have previously reported that restraint stress applied to the gestant mother results in long-lasting effects in the offspring that show an increase in the number of dopamine D2-type receptors in limbic areas on the adult rat brain cortex. Evidence that stress during pregnancy results in activation of the hypothalamic-pituitary-adrenal (HPA) axis has been extensively demonstrated. Therefore, high levels of corticosterone secreted in response to stress by the gestant mother might be one of the predisposing factors for the changes observed in dopamine receptors in the adult rat brain. In this study we addressed the question whether corticosterone would directly up-regulate D2-type receptors in vitro. We have investigated the effect of different concentrations of corticosterone on D4 dopamine receptor in immortalized cell lines from cerebral cortex of normal mouse fetuses, detected by immunocytochemistry employing polyclonal antibodies generated against synthetic peptides homologous to an extracellular domain of D4 receptor. The results show that corticosterone in vitro decreases the number of dopamine D4 receptors, suggesting that the increase of D2-type receptors in adult rats following prenatal stress is not related to a direct action of corticosterone on receptor expression.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Cerebral Cortex/metabolism , Corticosterone/pharmacology , Down-Regulation/drug effects , Neurons/metabolism , Receptors, Dopamine D2/biosynthesis , Animals , Cell Division/drug effects , Cell Line , Cerebral Cortex/cytology , Cerebral Cortex/drug effects , Female , Immunohistochemistry , Mice , Neurons/drug effects , Pregnancy , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D4
SELECTION OF CITATIONS
SEARCH DETAIL
...